Actuate Therapeutics, a clinical stage biopharmaceutical company focused on developing therapies for the treatment of “high impact, difficult to treat cancers,” priced its initial public offering of 2.8M shares at a price of $8.00 per share. The shares are trading on the Nasdaq under the symbol “ACTU.” Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. Newbridge Securities is acting as co-manager.